Debrisoquine oxidation phenotype during neuroleptic monotherapy.

Spina, E; Martines, C; Caputi, A P; Cobaleda, J; Piñas, B; Carrillo, J A; Benitez, J

Spina, E; Martines, C; Caputi, A P; Cobaleda, J; Piñas, B; Carrillo, J A; Benitez, J.

Affiliation

Spina E; Institute of Pharmacology, School of Medicine, University of Messina, Italy.

Eur J Clin Pharmacol ; 41(5): 467-70, 1991.

Article in En | MEDLINE | ID: mdl-1684751

Subject(s)

Antipsychotic Agents/pharmacology; Debrisoquin/metabolism; Adult; Aged; Cytochrome P-450 Enzyme System/physiology; Female; Humans; Male; Middle Aged; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Thioridazine/pharmacology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antipsychotic Agents / Debrisoquin Type of study: Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Clin Pharmacol Year: 1991 Document type: Article Affiliation country: Italy Country of publication: Germany

Search on Google

Add to My VHL

XML

PubMed Links